Jim Cramer on Novo Nordisk: "We're Not Novo People"

Novo Nordisk A/S (NYSE:NVO) is one of the 17 stocks that Jim Cramer commented on. During the episode, Cramer said that he prefers Eli Lilly to Novo Nordisk A/S (NYSE:NVO). He commented, “Novo Nordisk, well, we’re not Novo people. We’re Eli Lilly people.”

Novo Nordisk (NYSE:NVO) develops and distributes pharmaceutical products for diabetes, obesity, cardiovascular conditions, and rare diseases. The company offers treatments, smart insulin solutions, and drug delivery devices. On May 2, Cramer had the following opinion on the company:

“Next, did Novo Nordisk deliver a knockout punch to Eli Lilly when it signed a deal to be the preferred GLP-1 supplier to CVS on Lilly’s earnings day, no less? What a comeuppance. I think there’s plenty of gas in the Lily tank, especially once it tells it’s, you know, once it’s got this pill formulation that’s going to be available next year. I think it’s going to matter tremendously.”

While we acknowledge the potential of NVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.